Novel dual agonist leads to notable IOP lowering
The drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
Take-home: The drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
Reviewed by Eydie G. Miller-Ellis, MD
Philadelphia-In a group of 123 patients, the drug ONO-9054 showed a greater reduction in IOP and a longer duration of IOP reduction compared with latanoprost (Xalatan, Pfizer), said Eydie G. Miller-Ellis, MD.
ONO-9054 is a highly selective and potent dual EP3 and FP prostanoid receptor agonist.
More:
“It’s hypothesized that agonist activity against EP3 and FP receptors might provide more sustained reduction in IOP than the FP agonist latanoprost,” said Dr. Miller-Ellis, chief, glaucoma service, and professor of clinical ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Two previous clinical trials have shown that ONO-9054 both increases uveoscleral and trabecular outflow in animals and that it is safe and well tolerated in healthy normotensive adults and subjects with open-angle glaucoma (OAG) and ocular hypertension.
Related:
The previous research has found IOP reductions both from single and repeated doses. The IOP reductions extended to 33 hours post-dose.
“There are clinically relevant reductions in IOP regardless of a.m. or p.m. dosing,” Dr. Miller-Ellis said.
Internal server error